Allarity Therapeutics Initiates SCLC Trial with Stenoparib and Temozolomide
Allarity Therapeutics announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investigator-initiated Phase 2 trial for the treatment of relapsed small cell lung cancer, SCLC. This trial is being conducted in collaboration with the U.S. Department of Veterans Affairs and is fully funded through the VA's Special Emphasis Panel on Precision Oncology. Patient recruitment is ongoing across 11 VA medical centers throughout the United States. "We are pleased to report that these patients have now received the first doses of stenoparib in combination with temozolomide. We are encouraged by the speed of enrollment, which reflects enthusiasm for this combination as well as the significant unmet medical need in relapsed small cell lung cancer," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. "Prior studies have combined PARP inhibitors and temozolomide with great early effect but were severely limited by the toxicities of the first-generation PARP inhibitors when combined with temozolomide. The clinical experience with stenoparib to date has shown that it is well tolerated and may therefore be an ideal agent for combination with temozolomide in relapsed SCLC."
Trade with 70% Backtested Accuracy
Analyst Views on ALLR
About ALLR
About the author
Allarity Therapeutics Advances Stenoparib with FDA Fast Track Designation
- Strategic Reset: Over the past two years, Allarity has focused on developing the dual-target inhibitor stenoparib, which has recently received FDA Fast Track Designation, marking a significant advancement in the treatment of ovarian cancer and expected to enhance market competitiveness.
- Clinical Outcomes: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival has not yet been reached, with follow-up exceeding 22 months, indicating the durability and efficacy of stenoparib, which could attract higher investment interest.
- New Indication Expansion: Allarity has begun exploring stenoparib's application in recurrent Small Cell Lung Cancer, signing a fully funded clinical trial agreement with the US Veteran's Administration, further broadening its market potential.
- Financial Stability: The company has strengthened its financial foundation by simplifying its capital structure, ensuring continued access to public markets, which is expected to provide robust support for future clinical development.
Allarity Therapeutics CEO Letter Highlights Progress Toward Stenoparib FDA Approval
- Strategic Reset: In 2024, Allarity undertook a strategic reset by focusing exclusively on stenoparib and shedding low-value programs, which enhanced its potential to treat complex cancers and laid a solid foundation for future clinical and regulatory success.
- Clinical Progress: In 2025, Allarity accelerated the FDA approval process for stenoparib while expanding its clinical potential into high-value indications like recurrent Small Cell Lung Cancer, further strengthening the company's financial health.
- Clinical Data: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival had not been reached, with some patients on therapy for over 30 months, underscoring stenoparib's tolerability and clinical benefit, thus supporting its advantages as a next-generation PARP inhibitor.
- Future Outlook: Looking ahead to 2026, Allarity plans to expedite the approval process for stenoparib and explore its applications in other cancer indications, aiming to enhance enterprise value and address significant unmet medical needs.
3 Penny Stocks to Keep an Eye On as of August 28, 2025
Penny Stocks to Watch: Allarity Therapeutics, Incannex Healthcare Limited, and Firefly Neuroscience are highlighted as penny stocks to monitor on August 28, 2025, based on their Dollar Volume and market activity.
Allarity Therapeutics Update: The company received Fast Track designation from the FDA for its cancer treatment stenoparib, leading to a significant stock price increase of over 11% and a Dollar Volume of $553.44 million.
Incannex Healthcare Performance: Despite a nearly 6% drop in stock price with a Dollar Volume of $351.47 million, Incannex previously announced positive Phase 2 trial results for its psilocybin-assisted therapy, which had caused a surge of nearly 26%.
Firefly Neuroscience Developments: Firefly's stock fell nearly 3% with a Dollar Volume of $226.16 million after launching its new EEG technology platform, CLEAR, which enhances data quality and processing speed for brain health solutions.
Tuesday's Major Stock Market Highlights: Morning News Summary!
Market Overview: The article highlights significant stock market stories that investors should be aware of on Tuesday.
TipRanks Contribution: TipRanks has compiled a list of the most relevant news and updates affecting the stock market today.
Investor Insights: The content aims to provide insights and information that could influence investment decisions.
Disclaimer: There is a disclaimer regarding the information provided, indicating it may not cover all aspects of the market.
Crude Oil Prices Fall 2%; US Durable Goods Orders Decrease in July
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite up by 0.2%, while the Dow Jones dipped slightly by 0.02%. The S&P 500 also saw a minor increase of 0.10%.
Sector Movements: Industrial shares rose by 0.6%, whereas energy stocks experienced a decline of 0.6%.
Durable Goods Orders: U.S. durable goods orders fell by 2.8% in July to $302.8 billion, following a significant revised drop of 9.4% in June.
Global Market Trends: European and Asian markets closed lower, with notable declines in major indices such as Spain's IBEX 35 and Japan's Nikkei 225, reflecting a broader trend of decreasing stock values internationally.
US Stocks Show Varied Performance; American Woodmark Reports Disappointing Sales
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones down 0.1%, while NASDAQ and S&P 500 also experienced slight declines.
Sector Movements: Industrials sector saw a 0.3% increase, whereas energy stocks fell by 0.6%.
Company Earnings Reports: American Woodmark Corp reported disappointing sales, missing analyst estimates, while Allarity Therapeutics and EchoStar Corporation saw significant stock price increases due to positive news.
Global Market Trends: European and Asian markets closed lower, with notable declines in major indices, and U.S. durable goods orders decreased by 2.8% in July.
Allarity Therapeutics Advances Stenoparib with FDA Fast Track Designation
- Strategic Reset: Over the past two years, Allarity has focused on developing the dual-target inhibitor stenoparib, which has recently received FDA Fast Track Designation, marking a significant advancement in the treatment of ovarian cancer and expected to enhance market competitiveness.
- Clinical Outcomes: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival has not yet been reached, with follow-up exceeding 22 months, indicating the durability and efficacy of stenoparib, which could attract higher investment interest.
- New Indication Expansion: Allarity has begun exploring stenoparib's application in recurrent Small Cell Lung Cancer, signing a fully funded clinical trial agreement with the US Veteran's Administration, further broadening its market potential.
- Financial Stability: The company has strengthened its financial foundation by simplifying its capital structure, ensuring continued access to public markets, which is expected to provide robust support for future clinical development.
Allarity Therapeutics CEO Letter Highlights Progress Toward Stenoparib FDA Approval
- Strategic Reset: In 2024, Allarity undertook a strategic reset by focusing exclusively on stenoparib and shedding low-value programs, which enhanced its potential to treat complex cancers and laid a solid foundation for future clinical and regulatory success.
- Clinical Progress: In 2025, Allarity accelerated the FDA approval process for stenoparib while expanding its clinical potential into high-value indications like recurrent Small Cell Lung Cancer, further strengthening the company's financial health.
- Clinical Data: At the AACR Special Conference, Allarity presented clinical data showing that median overall survival had not been reached, with some patients on therapy for over 30 months, underscoring stenoparib's tolerability and clinical benefit, thus supporting its advantages as a next-generation PARP inhibitor.
- Future Outlook: Looking ahead to 2026, Allarity plans to expedite the approval process for stenoparib and explore its applications in other cancer indications, aiming to enhance enterprise value and address significant unmet medical needs.
3 Penny Stocks to Keep an Eye On as of August 28, 2025
Penny Stocks to Watch: Allarity Therapeutics, Incannex Healthcare Limited, and Firefly Neuroscience are highlighted as penny stocks to monitor on August 28, 2025, based on their Dollar Volume and market activity.
Allarity Therapeutics Update: The company received Fast Track designation from the FDA for its cancer treatment stenoparib, leading to a significant stock price increase of over 11% and a Dollar Volume of $553.44 million.
Incannex Healthcare Performance: Despite a nearly 6% drop in stock price with a Dollar Volume of $351.47 million, Incannex previously announced positive Phase 2 trial results for its psilocybin-assisted therapy, which had caused a surge of nearly 26%.
Firefly Neuroscience Developments: Firefly's stock fell nearly 3% with a Dollar Volume of $226.16 million after launching its new EEG technology platform, CLEAR, which enhances data quality and processing speed for brain health solutions.
Tuesday's Major Stock Market Highlights: Morning News Summary!
Market Overview: The article highlights significant stock market stories that investors should be aware of on Tuesday.
TipRanks Contribution: TipRanks has compiled a list of the most relevant news and updates affecting the stock market today.
Investor Insights: The content aims to provide insights and information that could influence investment decisions.
Disclaimer: There is a disclaimer regarding the information provided, indicating it may not cover all aspects of the market.
Crude Oil Prices Fall 2%; US Durable Goods Orders Decrease in July
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite up by 0.2%, while the Dow Jones dipped slightly by 0.02%. The S&P 500 also saw a minor increase of 0.10%.
Sector Movements: Industrial shares rose by 0.6%, whereas energy stocks experienced a decline of 0.6%.
Durable Goods Orders: U.S. durable goods orders fell by 2.8% in July to $302.8 billion, following a significant revised drop of 9.4% in June.
Global Market Trends: European and Asian markets closed lower, with notable declines in major indices such as Spain's IBEX 35 and Japan's Nikkei 225, reflecting a broader trend of decreasing stock values internationally.
US Stocks Show Varied Performance; American Woodmark Reports Disappointing Sales
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones down 0.1%, while NASDAQ and S&P 500 also experienced slight declines.
Sector Movements: Industrials sector saw a 0.3% increase, whereas energy stocks fell by 0.6%.
Company Earnings Reports: American Woodmark Corp reported disappointing sales, missing analyst estimates, while Allarity Therapeutics and EchoStar Corporation saw significant stock price increases due to positive news.
Global Market Trends: European and Asian markets closed lower, with notable declines in major indices, and U.S. durable goods orders decreased by 2.8% in July.
